Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Advanced Neuroresearch Therapeutics LLC maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This specific matter is assigned to 1 distinct examiner, JOHNSON, TIRONE DEREK. The prosecution footprint is limited to 1 distinct art unit, reflecting a concentrated examination environment. JOHNSON, TIRONE DEREK serves as the busiest examiner for the company, with 1 busiest examiner pending office action.
This alignment between the 1 pending office action and the busiest examiner's workload confirms that all current USPTO engagement is managed by a single individual. For a patent practitioner, this concentration suggests that the outcome of the current portfolio activity depends entirely on the interpretation of 1 distinct examiner within 1 distinct art unit. The Biotechnology & Pharmaceuticals focus remains consistent across this singular point of contact. This lack of examiner diversity requires a highly tailored approach to the specific preferences of the assigned official. Practitioners should prepare for a focused dialogue within this specific art unit to advance the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17734777 | METHODS FOR TREATING BRAIN INJURY OR COGNITIVE DYSFUNCTION BY PHARMACOLOGICAL ENHANCMENT OF M-TYPE POTASSIUM ION CURRENTS IN NEURONS | JOHNSON, TIRONE DEREK | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17734777 | METHODS FOR TREATING BRAIN INJURY OR COGNITIVE DYSFUNCTION BY PHARMACOLOGICAL ENHANCMENT OF M-TYPE POTASSIUM ION CURRENTS IN NEURONS | JOHNSON, TIRONE DEREK | 1675 | §102§103 | Final Rejection | — | Pending | May 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdvanced Neuroresearch Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tirone Derek Johnson has the most, with 1 of Advanced Neuroresearch Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
